teplizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
monoclonal antibodies (humanized origin); lymphocyte	5692	876387-05-2

Description:

Molecule	Description
Molfile Synonyms: teplizumab teplizumab-mzwv tzield MGA031	Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older with Stage 2 type 1 diabetes. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

teplizumab
teplizumab-mzwv
tzield
MGA031

Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older with Stage 2 type 1 diabetes. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 17, 2022	FDA	PROVENTION BIO INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 1	indication	46635009	DOID:9744

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
T-cell surface glycoprotein CD3	Surface antigen	P07766 P09693 P04234	CD3E_HUMAN CD3G_HUMAN CD3D_HUMAN	BINDING AGENT	Kd	5.64		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
CHEMBL1743078	ChEMBL_ID
C502540	MESH_SUPPLEMENTAL_RECORD_UI
12252	IUPHAR_LIGAND_ID
DB06606	DRUGBANK_ID
019232	NDDF
4041858	VANDF
4041859	VANDF
C2743673	UMLSCUI
8869	INN_ID
D09013	KEGG_DRUG
2621880	RXNORM
363273	MMSL
41083	MMSL
d09948	MMSL
S4M959U2IJ	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TZIELD	HUMAN PRESCRIPTION DRUG LABEL	1	73650-316	INJECTION	1 mg	INTRAVENOUS	BLA	25 sections